BNT162b2
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SARS-CoV-2 Infection, COVID19
Conditions
SARS-CoV-2 Infection, COVID19
Trial Timeline
Oct 15, 2021 → Jul 23, 2023
NCT ID
NCT04895982About BNT162b2
BNT162b2 is a phase 2 stage product being developed by Pfizer for SARS-CoV-2 Infection, COVID19. The current trial status is completed. This product is registered under clinical trial identifier NCT04895982. Target conditions include SARS-CoV-2 Infection, COVID19.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06923137 | Pre-clinical | Active |
| NCT05621239 | Pre-clinical | Completed |
| NCT04895982 | Phase 2 | Completed |
| NCT04880447 | Pre-clinical | Completed |
| NCT04816669 | Phase 3 | Completed |
| NCT04815031 | Pre-clinical | Completed |
| NCT04754594 | Phase 2/3 | Completed |
| NCT04588480 | Approved | Completed |
Competing Products
20 competing products in SARS-CoV-2 Infection, COVID19